Will Spain put an end to Alzheimer’s?
Early diagnosis of this disease is one of the factors that would enable better treatment. This is a key focus of many of the biotechnology companies that have emerged in recent decades. In Spain and in other countries, several research projects are currently underway,...
CTAD 2014 presentation of a blood-based 7-metabolite signature for the early diagnosis of Alzheimer´s disease.
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing...
Biocross is involved in a new clinical study
Biocross is involved in a new multicenter study in which 17 hospitals from Spain, France, and Belgium are participating. The objective is to recruit over 500 patients, classified as healthy individuals or patients with AD, mild cognitive impairment, or other...
